The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'


AstraZeneca and Daiichi Sankyo field backlash over Super Bowl OIC awareness ad.....           Lilly suffers stinging defeat in EU patent battle over Alimta.....           Burwell says HHS is considering 'march-in' on skyrocketing drug prices.....           U.K. slaps GSK with $54.4M fine for decade-old pay-for-delay deal.....           Novartis takes aim at Remicade market with EU biosim rights from Pfizer.....           Sun sales in U.S. fall further as FDA issues linger.....           University of Michigan forms chronic kidney disease consortium with pharma companies.....           Incyte to stop Janus studies of Ruxolitinib in solid tumor cancers.....           EMA accepts Sandoz application for biosimilar to Amgen's Neulasta cancer drug.....           RedHill Biopharma completes pharmacokinetic study with BEKINDA 12 mg formulation.....           Crown Bioscience to commercialize University of York's prostate cancer models.....           ONL Therapeutics gets FDA orphan drug designation for ONL1204 to treat retinal detachment.....           NanoViricides inks deal with University of Pittsburgh for ocular resting of drug candidates.....           Big Pharma shells out big campaign dollars to presidential candidates.....           Imprimis targets another Shkreli price hike with compounded rival to $30-per-pill Thiola.....           With Baxalta in hand, Shire's not looking to buy. But sell? Maybe.....           Incyte bags more Jakafi studies in solid tumors, but maintains hope for combo success.....           Teva's Copaxone finally succumbs to copycats, putting a drag on 2015 sales.....           FDA halts clinical trial of CTI Biopharma?s blood cancer drug.....           Mylan offers to buy Meda for $7.2bn.....           Imprimis plans to make cheaper alternative to Retrophin's Thiola kidney stone drug.....           Bayer HealthCare selects Oracle solutions to manage clinical monitoring processes.....           Theravance achieves 50% enrollment in all three phase 3 studies of Revefenacin.....           Cellceutix meets with FDA for phase 2 clinical trial of Kevetrin for ovarian cancer.....           Lonza, Renova sign manufacturing deal for clinical supply of RT-100 gene therapy.....           Amarantus gets FDA orphan drug designation for Eltoprazine to treat PD-LID.....           Hikma slashes $535M from offer price for Boehringer's U.S. generics biz.....           Novartis defies naysayers with newfangled pay-for-performance deals on Entresto.....           FDA vote sets stage for J&J and Pfizer battle over Remicade's $6.5B in sales.....           Recent controversy hasn't hurt brand value for Pfizer, Valeant: report.....           Medicare may experiment with caps to cancer-drug reimbursements.....           Sanofi tried and failed with Afrezza. Why does MannKind still think it can win?.....           Mylan snags Meda, advances its OTC ambitions, with $7.2B deal.....           US FDA delays decision on Sarepta Therapeutics? drug to treat muscular dystrophy.....           Tobira Therapeutics completes patient recruitment for ORION Phase 2a study of cenicriviroc.....           SMC accepts treatments for breast cancer, myeloma and ADHD.....           Pharming and Cytobioteck extened distribution agreement for Ruconest.....           Nymox announces prostate cancer clinical trial results.....           Hemispherx Biopharma exploring possible research programs in Zika virus.....           CTI BioPharma provides update on clinical hold of investigational agent Pacritinib.....           Cigna and Aetna sign pay-for-performance deal with Novartis for Entresto drug.....           UK health agency rejects Sanofi?s cholesterol drug.....           Sanofi's outlook less than sunny as key diabetes franchise continues to sag.....           Top Senate Democrat grills HHS about opioid panel's alleged ties to industry.....           After a big 2015, Regeneron predicts slowing 2016 sales for launch superstar Eylea.....           Sanofi scarce on turnaround details, but left a few needles in the Q4 haystack.....           FDA warning letter puts Ipca Labs under fire for widespread data manipulation.....           Actelion exceeds profit estimates as Opsumit, Uptravi make up for aged Tracleer.....           Volpi, Qiagen team up to manufacture automated fluorescence imaging module.....           US FDA imposes partial hold on CTI BioPharma's pacritinib clinical trial.....           NICE issues draft guidance on alirocumab for lipid disorder.....           Kodiak Sciences partners with Lonza.....           Egalet signs agreement with Septodont.....           CytRx secures $40m long-term loan facility.....           EU drug agency establishes task force to fast-track trials on Zika virus.....           UPDATED: NICE, in reversal, OKs Amgen's Repatha while snubbing Sanofi and Regeneron's Praluent.....           ImmunoGen signs clinical research collaboration agreement with MRK.....           FDA approves Bristol Myers Squibb?s Daklinza?s for expanded use to treat patients with hepatitis C.....           Affinivax gets additional funding to advance its pneumococcal vaccine.....           Takeda-Teva JV 'could be a trendsetter' as Japan pushes for generics: analyst.....           Doctors pounce on 'alarmist,' 'horrifying' Novartis heart-failure ad.....           PhRMA kicks off new ad campaign to doctor pharma's tarred image.....           NICE, in reversal, OKs Amgen's Repatha while snubbing Sanofi and Regeneron's Praluent.....           Top exec exits as Pfizer redraws org chart for post-megamerger future.....           Some top GSK investors aren't sold on a breakup--and they're backing CEO Witty, too.....           Pfizer builds on early Ibrance lead as Novartis, Lilly rivals inch closer.....           FDA declines to approve Vertex's Kalydeco in people with cystic fibrosis ages 2 and older.....           Catabasis, MDA partner to develop novel oral disease-modifying treatment for DMD.....           AstraZeneca CEO still interested in M&A but he is getting very picky.....           EMA: Faulty device didn't distort study findings for Bayer's Xarelto.....           Seattle Genetics unveils commercial and regulatory progress under ADCETRIS collaboration with Takeda.....           AstraZeneca CEO still interested in M&A but he is getting very picky.....           FDA shoots down Vertex's latest bid for Kalydeco expansion.....           Celltrion's biosimilar of J&J's Remicade reviewed favorably by FDA staffers.....           EMA: Faulty device didn't distort study findings for Bayer's Xarelto.....           FDA expands indication for Merck's Emend nausea and vomiting drug.....           Sigmoid Pharma agrees to acquire Freund Pharmatec.....           Bavarian Nordic enters research partnership to develop MRSA vaccine.....           AAI/CML unveil new offering for solid state chemistry and formulation development.....           Juventas enrolls first patient in phase 2 gene therapy clinical trial.....           Cancer Research UK starts phase 1/1b clinical trial of taladegib in combination with paclitaxel.....           US FDA advisory committee votes in favor for Takeda and Lundbeck's Brintellix.....           Patent losses looming, AZ fights back with Brilinta, diabetes and China.....           Blockbuster new launches coming from Intercept, Gilead and Merck: Reuters.....           Media-magnet hearing on Capitol Hill gets underway, with Valeant, Turing under spotlight.....           FDA panel backs game-changing cognitive claim for Lundbeck antidepressant Brintellix.....           J&J chief shells out $9M for Manhattan condo.....           Valeant chief calls on Medicare to allow controversial copay help from pharma.....           Valeant, Turing slammed for price hikes during congressional hearing.....           FDA's Califf calls for 'sweeping re-examination' of policies in effort to fight opioid abuse.....           Indian firm develops two Zika vaccines.....           Cytori Cell Therapy found safe in phase I erectile dysfunction trial.....           Fast Forward Pharmaceuticals starts phase II trials of FFP104 anti-CD40 monoclonal antibody.....           ViaCyte acquires rights to BetaLogics assets from Janssen.....           EC approves TAGRISSO to treat patients with EGFR T790M mutation-positive NSCLC.....           Arch Biopartners submits AB569 orphan drug application to EMA.....           Eisai, Esteve sign deal to co-promote anti-epilepsy drug Fycompa in Spain.....           Takeda secures rights to Mersana?s XMT-1522 outside US and Canada.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
 
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
 
 
Recent meetings

APS 20th Anniversary International Pharmaceutical Photostability Conference 2015
5-7 October 2015 - Loughborough

In this International Year of Light 2015, the APS was particularly pleased to present this event, which was a one-day workshop and a two-day conference.
The course was suitable for those who are new to the topic of pharmaceutical photostability and photostability testing and also for those who wished to brush up on the basic concepts prior to the PPS’015 conference that followed it.

Read more...


6th APS International PharmSci Conference
7-9 September 2015 - Nottingham

The 6Th APS International PharmSci Conference - A summary from David Jones, Science Chair 2015

It has been my great pleasure and indeed honour to be the Chairman of this year’s APS conference. The excellent programme, involving both national and international contributors, was beautifully complemented by the wonderful energy and enthusiasm of all delegates. The scope of scientific disciplines was wide and encompassed many key themes of the pharmaceutical sciences including, drugs from natural sources, solid state pharmaceutics, formulation science, pharmaceutical analysis, pharmaceutical microbiology, nanosciences and material sciences, to name but a few.

Read more...


6th APS International PharmSci Conference
7-9 September 2015 - Nottingham

Exploring The 6Th APS International PharmSci Conference - A Hugh Success…

An overview from Bill Dawson, APS Chair

The flagship Academy conference was a huge success, building on its previous strengths on its return to the East Midlands Conference Centre in Nottingham. The balance between academia and industry was maintained and many young pharmaceutical scientists had their first opportunity to present either poster or podium presentation which is a major strength of PharmSci.

Read more...

Latest News
APS Industrial Insights 2016
THURSDAY, 11 FEBRUARY 2016
GSK, Ware Monday 11th-Tuesday 12th April 2016. Industrial Insights is a two day event for undergraduate and postgraduate students interested in exploring opportunities in the Pharmaceutical Industry. As a student attending the event, you will be able to gain first-hand insight into the Pharmaceutical Industry through a series of talks by pharmaceutical scientists working within the industry as well as a tour of the GSK Research and Development and Global Manufacturing site at Ware in Hertfordshire. Choosing the right career path...A done deal or still deciding? Industrial Insights 2016 offers opportunities to network with experienced pharmaceutical scientists including members of the NSFG committee, and have your CV reviewed by an industry professional. Industrial Insights is organised by The Academy of Pharmaceutical Sciences New Scientist Focus Group (NSFG). Feedback from Industrial Insights 2015 “As someone who has only just started working in the pharmaceutical industry, to hear from a range of speakers at different parts of their career and in different parts of the sector was invaluable” “The Industrial Insights conference represents an exciting and unique opportunity for those wishing to begin a career in the Pharmaceutical Industry. The conference provides an insight into a variety of disciplines, and I found it engaging, relevant and informative. A particular highlight for me was the insight into diverse career opportunities available, many of which I had little prior experience of. Such an insight has been instrumental in guiding my current career ambitions” For further information please visit us online: https://www.apsgb.co.uk/Events/20160411/ Registrations are now open and Early Bird fees apply until 31 March 2016.
New Edition of the Pre-registration Pharmacist Industry Information Pack
WEDNESDAY, 10 FEBRUARY 2016
The APS would like to notify all undergraduate Pharmacy Students interested in a career in the Pharmaceutical Industry that a new edition of the Pre-registration Pharmacist Industry Information Pack is now available.. From the booklet. ‘The aim of this brochure is to tell you a little about the global pharmaceutical companies that offer pre-registration Pharmacist training; namely AstraZeneca, Bristol-Myers Squibb, GSK, MSD and Pfizer. It also includes information on the wide range of roles carried out by scientists in the pharmaceutical industry and provides answers to some of your frequently asked questions. We also recognise. that you may be attending interviews or applying for jobs for the first time, so we have included our Candidates Interview Handbook to assist you in preparing for those crucial interviews. We hope you will find this booklet useful.’. Please find a copy at: http://www.apsgb.co.uk/resources/flyers.asp.
APS MANUFACTURING CLASSIFICATION SYSTEM (MCS)
MONDAY, 25 JANUARY 2016
‘A proposal for a drug product Manufacturing Classification System (MCS) for oral solid dosage forms’, was the most downloaded article in Pharmaceutical Development & Technology, for 2015.. The APS is pleased to announce that), Dr Michael Leane (BMS), Dr Kendal Pitt (GSK) and Dr Gavin Reynolds (Astra Zeneca) have been congratulated by Charles Whalley - Managing Editor, Medicine & Health Science Journals that a paper resulting from, an ongoing successful joint APS focus group collaboration between the Material Science and Process Engineering and Product Formulation Focus Groups,entitled ‘A proposal for a drug product Manufacturing Classification System (MCS) for oral solid dosage forms was the most downloaded article in the journal last year.. They were thanked for their contributing to the growing success of Pharmaceutical Development & Technology. Hoping to see more submissions from them in future!. Information about the APS MANUFACTURING CLASSIFICATION SYSTEM (MCS). The MCS, is a successful joint APS focus group collaboration between the Material Science and Process Engineering and Product Formulation Focus Groups, led by Michael Leane (BMS), Kendal Pitt (GSK) and Gavin Reynolds (Astra Zeneca). It began in June2013 after a joint meeting between the groups and has expanded internationally, enabling a wealth of discussion and knowledge to be captured. The MCS is intended as a tool for pharmaceutical scientists to rank the feasibility of different processing routes for the manufacture of oral solid dosage forms, based on selected properties of the API and the needs of the formulation. The proposed MCS could be used to develop a risk assessment for manufacturing and also indicate how robust a manufacturing process is likely to be. This resulted in a white paper, Pharm Dev Technology, 2015:20(1)12-21. The authors have presented at meetings to encourage active participation and discussion. For 2015, the following programme has been undertaken IFPAC, Washington DC 25th - 28th Jan 2015; APS Particle Engineering, Dublin April 2015; IPS-FIP/ANVISA; Brasilia, 22nd -23rd June2015APS PharmSci Conference Sept 2015 FIP;Dusseldorf, 28 Sept - 3rd Oct 2015. The next stage is to Issue a 2nd follow-up paper to extend to Hot Melt and Fluid Bed Granulation and Continuous manufacture.. Input is very much valued and can be either emailed to mcs@apsgb.org or input into a survey to include your comments. https://www.surveymonkey.com/s/57GGL8K.
APS PharmaFocus Day
FRIDAY, 22 JANUARY 2016
Pfizer, Discovery Park, Sandwich Wednesday 24th February 2016. The New Scientists Focus Group of the APS is pleased to offer students a unique opportunity to visit the Pfizer Research and Development site at Discovery Park in Sandwich.. During the visit, students will have a chance to tour the facilities, network with industrial pharmaceutical scientists and learn about career options in the pharmaceutical industry.. Registration for this is event is limited to 20 places so early booking is recommended.. Visit us online for more information: https://www.apsgb.co.uk/Events/20160224/. .
 
Follow us
 
Upcoming Events
APS PharmaFocus Day
24 February 2016
APS Industrial Insights 2016
11 - 12 April 2016
APS Board, Advisory Board & ELT Meeting
18 - 19 April 2016
Delivery of High Dose Inhaled Drugs
Spring 2016
Basic Biopharmaceutics Workshop
Spring 2016
Job Vacancies
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.

 

The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365
Email: info@apsgb.org

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.